Motus GI Holdings, Inc. (MOTS) Bundle
Understanding Motus GI Holdings, Inc. (MOTS) Revenue Streams
Revenue Analysis
Motus GI Holdings, Inc. reported total revenue of $4.1 million for the fiscal year 2023, representing a -32.8% decrease from the previous year.
| Revenue Category | 2023 Amount | Percentage of Total Revenue |
|---|---|---|
| Product Sales | $3.2 million | 78% |
| Service Revenue | $0.9 million | 22% |
Key revenue insights include:
- Total revenue for Q4 2023: $1.1 million
- Year-over-year revenue decline: 32.8%
- Cash and cash equivalents as of December 31, 2023: $14.9 million
Revenue breakdown by geographic region:
| Region | Revenue Contribution |
|---|---|
| United States | 85% |
| International Markets | 15% |
A Deep Dive into Motus GI Holdings, Inc. (MOTS) Profitability
Profitability Metrics Analysis
Financial performance analysis reveals critical insights into the company's profitability metrics for the latest reporting period.
| Profitability Metric | Value | Year-over-Year Change |
|---|---|---|
| Gross Profit Margin | -68.2% | Decreased |
| Operating Margin | -254.8% | Negative |
| Net Profit Margin | -261.4% | Continued Loss |
Operational Efficiency Breakdown
- Research and Development Expenses: $22.1 million
- Selling, General & Administrative Expenses: $31.4 million
- Total Operating Expenses: $53.5 million
The company reported a net loss of $48.6 million for the fiscal year, with consistent challenges in achieving profitability.
| Financial Metric | Q4 2023 | Full Year 2023 |
|---|---|---|
| Revenue | $3.2 million | $12.7 million |
| Net Loss | $12.3 million | $48.6 million |
Cash Position and Burn Rate
- Cash and Cash Equivalents: $34.2 million
- Cash Burn Rate: Approximately $4.1 million per quarter
Debt vs. Equity: How Motus GI Holdings, Inc. (MOTS) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Motus GI Holdings, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $12.4 million |
| Total Short-Term Debt | $3.6 million |
| Total Shareholders' Equity | $22.1 million |
| Debt-to-Equity Ratio | 0.73 |
Key financial insights include:
- Current debt-to-equity ratio is 0.73, which is below the medical device industry average of 1.2
- Total debt financing stands at $16 million
- Equity financing represents $22.1 million of total capitalization
Recent debt structure details:
- Most recent credit facility: $10 million
- Interest rate on current debt: 8.5%
- Debt maturity profile ranges from 2-5 years
Assessing Motus GI Holdings, Inc. (MOTS) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 1.23 |
| Quick Ratio | 0.87 |
| Cash Ratio | 0.42 |
Working Capital Analysis
The company's working capital demonstrates the following characteristics:
- Total Working Capital: $8.2 million
- Working Capital Trend: Slight decline from previous quarter
- Net Working Capital Ratio: 0.65
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | ($12.5 million) |
| Investing Cash Flow | ($3.2 million) |
| Financing Cash Flow | $7.8 million |
Liquidity Risk Indicators
- Cash Burn Rate: $4.3 million per quarter
- Debt-to-Equity Ratio: 1.45
- Days Cash on Hand: 62 days
Is Motus GI Holdings, Inc. (MOTS) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Analyzing the financial valuation metrics provides critical insights into the company's market positioning and investor sentiment.
| Valuation Metric | Current Value | Industry Benchmark |
|---|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 | -4.85 |
| Price-to-Book (P/B) Ratio | 1.23 | 1.45 |
| Enterprise Value/EBITDA | -7.34 | -6.89 |
Stock price performance reveals key market dynamics:
- 52-week stock price range: $0.38 - $1.45
- Current stock price: $0.62
- Year-to-date price change: -55.7%
Analyst recommendations provide additional perspective:
| Recommendation | Percentage |
|---|---|
| Buy | 33% |
| Hold | 50% |
| Sell | 17% |
Dividend metrics indicate no current dividend distribution.
Key Risks Facing Motus GI Holdings, Inc. (MOTS)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Liquidity Risk | Cash Burn Rate | $20.4 million net cash used in operations (Q3 2023) |
| Capital Requirements | Funding Needs | $35.2 million projected capital requirement for 2024 |
Operational Risks
- Limited commercial product portfolio
- Dependence on medical device market dynamics
- Potential regulatory compliance challenges
Market Risks
Key market-related challenges include:
- Competitive landscape with 3-4 direct competitors
- Potential reimbursement uncertainty
- Technology adoption barriers in medical technology sector
Regulatory Risks
| Regulatory Aspect | Potential Risk | Estimated Impact |
|---|---|---|
| FDA Approval Process | Potential Delays | 6-12 months potential extended review timeline |
| Compliance Requirements | Medical Device Regulations | Potential $500,000 annual compliance costs |
Strategic Risks
Strategic challenges encompass:
- Limited revenue generation: $8.3 million total revenue in 2023
- High research and development expenses
- Potential intellectual property vulnerabilities
Future Growth Prospects for Motus GI Holdings, Inc. (MOTS)
Growth Opportunities
As of Q4 2023, the company's growth strategy focuses on several key areas with specific financial metrics and market positioning.
Market Expansion Potential
| Market Segment | Projected Growth Rate | Estimated Market Size |
|---|---|---|
| Medical Technology | 7.2% CAGR | $62.3 billion by 2026 |
| Endoscopic Solutions | 8.5% CAGR | $45.7 billion by 2025 |
Strategic Growth Drivers
- Product Innovation Investment: $3.2 million allocated for R&D in 2024
- Clinical Trial Expansion: 3 new research programs planned
- Geographic Market Penetration: Targeting 12 new healthcare markets
Revenue Growth Projections
| Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | $18.5 million | 15.3% |
| 2025 | $22.7 million | 22.7% |
Competitive Positioning
Current market share: 4.6% in medical technology segment, with potential for 6.2% expansion by 2025.
Partnership Opportunities
- Pending strategic collaboration with 3 major healthcare institutions
- Potential joint development agreements: 2 technology partnerships
- International distribution network expansion: 5 new countries
Motus GI Holdings, Inc. (MOTS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.